Novo’s Low-Cost Wegovy Offers Alternative To Compounders For Self-Pay Crowd

Five Doses Available At $499 Per Month

 
• By Mandy Jackson
  
Novo's lower-cost Wegovy options will be offered in pens while Lilly's cash-pay Zepbound products are in vials (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

More from Business